Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer



Status:Active, not recruiting
Conditions:Colorectal Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/14/2018
Start Date:July 2009
End Date:July 2020

Use our guide to learn which trials are right for you!

A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer

RATIONALE: Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Monoclonal antibodies, such as panitumumab, can block tumor
growth in different ways. Some block the ability of tumor cells to grow and spread. Others
find tumor cells and help kill them or carry tumor-killing substances to them. Panitumumab
may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Drugs used
in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth
of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet
known whether erlotinib hydrochloride given together with panitumumab is more effective with
or without irinotecan in treating patients with metastatic colorectal cancer.

PURPOSE: This randomized phase II trial is studying giving erlotinib hydrochloride together
with panitumumab to see how well it works with or without irinotecan hydrochloride as
second-line therapy in treating patients with metastatic colorectal cancer.

OBJECTIVES:

Primary

- Determine the response rate in patients with metastatic colorectal cancer treated with
erlotinib hydrochloride and panitumumab with versus without irinotecan hydrochloride as
second-line therapy .

Secondary

- Determine time to disease progression and time to treatment failure in patients treated
with these regimens.

- Determine the safety of these regimens in these patients.

- Determine the effect of these regimens on downstream targets of EGFR in skin rash
associated with pharmacologic EGFR inhibition (exploratory).

- Determine the association between KRAS mutations and response to EGFR inhibition
(exploratory).

OUTLINE: This is a multicenter study. Patients are stratified according to wild-type Kras
tumors ( 6/6 UGT1A1 vs 6/7 UGT1A1), and are randomized to 1 of 2 treatment arms. Patients
with wild-type Kras tumor 7/7 UGT1A1 receive treatment in arm III.

- Arm I: Patients receive oral erlotinib hydrochloride once daily on days 1-14,
panitumumab IV over 30-90 minutes on day 1, and irinotecan hydrochloride IV over 90
minutes on day 1. Treatment repeats every 2 weeks in the absence of disease progression
or unacceptable toxicity.

- Arm II: Patients receive oral erlotinib hydrochloride once daily on days 1-14 and
panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks in the
absence of disease progression or unacceptable toxicity. Upon disease progression,
patients receive irinotecan hydrochloride as in arm I.

- Arm III: Patients receive erlotinib hydrochloride and panitumumab as in arm II. Skin
biopsies and blood samples may be collected for further analysis.

After completion of study therapy, patients are followed every 6 weeks.

DISEASE CHARACTERISTICS:

- Histologically confirmed colorectal cancer

- Metastatic disease

- Biopsy of either the primary cancer or metastatic site required

- Tumor expressing wild-type Kras mutations

- Progressive disease within 3 months after treatment with first-line fluorouracil
(5-FU) and oxaliplatin-based chemotherapy OR evidence of metastatic disease within 6
months of completing adjuvant therapy with 5-FU and oxaliplatin

- Measurable disease defined as ≥ 1 lesion that can be accurately measured in ≥ 1
dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques OR
as ≥ 10 mm with spiral CT scan

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Life expectancy > 6 months

- ANC > 1,500/mm^3

- Platelet count > 100,000/mm^3

- Hemoglobin ≥ 9 g/dL

- Creatinine < 1.5 times upper limit of normal (ULN)

- Bilirubin < 1.5 times ULN (or < 2 mg/dL)

- AST and/or ALT < 3 times ULN (< 5 times ULN with liver metastases)

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No concurrent malignancy requiring therapy except minor surgery for non-melanoma skin
cancer removal

- No interstitial lung disease with symptoms (e.g., dyspnea or cough) including any of
the following significant conditions:

- Parenchymal lung disease

- Metastatic disease

- Pulmonary infections

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior EGFR inhibitors, irinotecan hydrochloride, or other second-line chemotherapy
regimens

- More than 4 weeks since prior radiotherapy

- No other concurrent investigational agents

- No other concurrent anticancer treatment modalities (e.g., radiotherapy)
We found this trial at
10
sites
Oklahoma City, Oklahoma 73120
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
?
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
676 N St Clair St #2140
Chicago, Illinois 60611
(312) 664-5400
Hematology and Oncology Associates Northwestern Medical Faculty Foundation (the Foundation) is a premier, multi-specialty physician...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Germantown, Tennessee 38138
?
mi
from
Germantown, TN
Click here to add this to my saved trials
?
mi
from
Joliet, IL
Click here to add this to my saved trials
?
mi
from
Mount Holly, NJ
Click here to add this to my saved trials
8303 Dodge Street
Omaha, Nebraska 68114
(402) 354–4000
Nebraska Methodist Hospital Methodist Hospital is a general medical and surgical hospital in Omaha, NE....
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Terre Haute, Indiana 47802
?
mi
from
Terre Haute, IN
Click here to add this to my saved trials
818 N. Emporia, #403
Wichita, Kansas 67214
(316) 262-4467
Cancer Center of Kansas The physicians of Cancer Center are hematologists and oncologists. The staff...
?
mi
from
Wichita, KS
Click here to add this to my saved trials